Cardiff Oncology
CRDF
66 hedge funds and large institutions have $40.5M invested in Cardiff Oncology in 2016 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 22 increasing their positions, 19 reducing their positions, and 7 closing their positions.
16% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 19
0% more funds holding
Funds holding: 66 → 66 (0)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
5% less capital invested
Capital invested by funds: $42.4M → $40.5M (-$1.92M)
91% less call options, than puts
Call options by funds: $60K | Put options by funds: $689K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$434K |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$170K |
| 3 |
DADC
D.A. Davidson & Co
Great Falls,
Montana
|
+$162K |
| 4 |
Millennium Management
New York
|
+$120K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$88.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$1.75M |
| 2 |
Goldman Sachs
New York
|
-$376K |
| 3 |
TCIM
TIAA CREF Investment Management
New York
|
-$260K |
| 4 |
HighTower Advisors
Chicago,
Illinois
|
-$119K |
| 5 |
FHC
First Heartland Consultants
Lake St. Louis,
Missouri
|
-$103K |
CRDF Hedge Fund Activity: Q3 2016 in Review
66 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Cardiff Oncology (CRDF) for Q3 2016, worth a combined $40.5M — down 4.5% from $42.4M a quarter earlier.
Fund positioning in CRDF was balanced in Q3 2016: 7 funds opened new positions, 7 closed out, 22 added to existing stakes and 19 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $434K. The largest seller was Morgan Stanley, cutting an estimated $1.75M.
- 66 institutional investors held Cardiff Oncology (CRDF) as of Q3 2016, unchanged from Q2 2016.
- Funds reported $40.5M of Cardiff Oncology stock for Q3 2016, down 4.5% quarter-over-quarter.
- 7 funds opened new Cardiff Oncology positions in Q3 2016 and 7 closed out, a net change of 0 holders.
- The largest Cardiff Oncology buyer in Q3 2016 was Susquehanna International Group, an estimated $434K added.
- The largest Cardiff Oncology seller in Q3 2016 was Morgan Stanley, an estimated $1.75M sold.
Based on aggregated 13F filings for Q3 2016.